News and Reports | August 25, 2026
Monday’s ruling was welcomed by advocacy group Patients for Affordable Drugs, whose director of media and communications, Emma Sands, said the pharma industry has spent three years and millions of dollars fighting the programme.
“Again and again, their arguments have failed in the courtroom,” Sands said. “This is a win for patients who fought for this program and are already seeing the lower prices it delivers.”
Sands argued in her statement that the programme is “overwhelmingly supported by American patients and Taxpayers,” adding further political pressure on drugmakers pursuing further legal challenges.